Related Experiment Video
Updated: Jun 20, 2026
09:04
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
[Methotrexate: safe if prescribed correctly].
Monique M Verduijn1, Bart J F van den Bemt, Ben A C Dijkmans
1Nederlands Huisartsen Genootschap, Utrecht, The Netherlands. m.verduijn@nhg.org
Nederlands Tijdschrift Voor Geneeskunde
|September 30, 2009
Summary
Methotrexate (MTX) prescriptions can be fatal if taken daily instead of weekly. Improved pharmacovigilance, clear instructions, and patient education are crucial to prevent medication errors with this important drug.
Area of Science:
- Rheumatology
- Dermatology
- Pharmacovigilance
Context:
- Methotrexate (MTX) is a widely used medication for rheumatoid arthritis and severe psoriasis.
- MTX is typically prescribed as a once-weekly dosage for most indications.
- Prescription errors, miscommunication, and inadequate patient knowledge have led to fatal incidents.
Purpose:
- To highlight the dangers of incorrect Methotrexate dosing.
- To emphasize the need for enhanced safety measures in MTX prescription and administration.
- To advocate for improved pharmacovigilance and patient education strategies.
Summary:
- Fatal incidents have occurred due to incorrect daily dosing of Methotrexate instead of the intended weekly dose.
- These errors stem from prescription mistakes, poor communication, insufficient pharmacovigilance, and lack of patient understanding.
- Implementing automatic pharmacovigilance, clear prescription instructions, and comprehensive patient information is essential.
Impact:
- Preventing fatal medication errors associated with Methotrexate.
- Enhancing patient safety in the management of chronic inflammatory conditions.
- Improving the overall effectiveness and safety profile of Methotrexate therapy through better adherence and understanding.
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:17Phase II Reactions: Methylation Reactions
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...